Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Stroke survivors were more likely to have little or no disability after 90 days if a clot was removed from a large brain artery followed by the injection of the clot-dissolving medication tenecteplase ...

The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...

Ischemic strokes occur when there is blocked blood flow to the brain, something that can result in permanent disability. Doctors can use certain medications to dissolve blood clots when they are the ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. THURSDAY, March 20, 2025 (HealthDay News) -- A newly approved clot- busting drug for ...

Please provide your email address to receive an email when new articles are posted on . The findings were presented in a poster at the American College of Allergy, Asthma & Immunology Annual ...

Compared with the standard clot-busting medication alteplase, the newer clot-buster known as tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) stroke in mobile ...

Two randomized trials found that intra-arterial urokinase and tenecteplase did not improve functional outcomes after mechanical thrombectomy in selected stroke patients. However, these results do not ...